Document is current
Any future updates will be listed below
-
Authors
Okamura, Emi
Harada, Norio https://orcid.org/0000-0001-8720-1013
Okuno, Kana
Yamamoto, Kana
Murakami, Takaaki https://orcid.org/0000-0003-3844-1138
Ueda, Yohei https://orcid.org/0000-0003-2197-2784
Yabe, Daisuke https://orcid.org/0000-0002-5334-7687
-
Funding
Funding for this research was provided by:
University of Fukui
- License Information
-
More Information
Article History
Received: 19 August 2025
Accepted: 6 November 2025
First Online: 29 December 2025
Declarations
:
: Formal ethics approval was waived from the ethics committee of Kyoto University Graduate School of Medicine because this is a case report.
: Written informed consent was obtained from the subject for publication of this report.
: DY received grants from the Japan Agency for Medical Research and Development, the Japan Association for Diabetes Education and Care, Japan Society of Metabolism and Clinical Nutrition, the Japan Society for the Promotion of Science, the Mampei Suzuki Foundation. DY also received consulting or speaker fees from Kansai Electric Power Medical Research Institute, Astrazeneca, Sanofi, Eli Lilly, Tanabe Mitsubishi Pharma, Ono Pharma, Kowa, Sumitomo Pharma, Boehringer Ingelheim, Astellas Pharma, MSD, Novo Nordisk, and Eli Lilly, and Takeda Pharmaceutical. DY took a leadership role in International Diabetes Federation Western Pacific Region (Executive Board Member), Asian Association for the Study of Diabetes (Executive Board Member), Japan Endocrine Society (Executive Board Member), Japan Association for Diabetes Education and care (Executive Board Member), Japan Society of Constitutional Medicine, Executive Board Member (Executive Board Member), and Japan Society of Metabolism and Clinical Nutrition (Executive Board Member). TM received grants from Sumitomo Pharma. EO, NH, KO, KY and YU declared no competing interest.
